ALAMEDA, Calif., Aug. 24, 2017 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following upcoming investor conferences: Event: Wells Fargo 2017 Healthcare Conference Location: Boston, MA at the Westin Boston Waterfront Date: Thursday, September 7, 2017 Time: 1:40pm ET / 10:40am PT Event: Morgan […]
Tag: Penumbra
Penumbra, Inc. Reports Second Quarter 2017 Financial Results
ALAMEDA, Calif., Aug. 8, 2017 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on interventional therapies, today reported financial results for the second quarter ended June 30, 2017. Revenue of $80.6 million in the second quarter of 2017, an increase of 23.8%, or 24.6% in constant currency1, over the second quarter of 2016. […]
Penumbra Schedules Second Quarter 2017 Earnings Release And Conference Call For August 8, 2017 At 4:30 PM Eastern Time
ALAMEDA, Calif., July 25, 2017 /PRNewswire/ — Penumbra, Inc.(NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2017 after market close on Tuesday, August 8, 2017 at 4:30 PM Eastern Time. A press release with second quarter 2017 financial results will be issued after market close […]
Penumbra initiates recall of 3D Revascularation Device
Penumbra Inc. Recalls 3D Revascularization Device Due to Wire Material That May Break or Separate During Use Penumbra Inc. is recalling the Penumbra 3D Revascularization device because there is a risk of the delivery wire breaking or separating during use. Fractured pieces of the delivery wire could be left inside […]
Penumbra Promotes Daniel Davis To Chief Commercial Officer
ALAMEDA, Calif., July 5, 2017 /PRNewswire/ Penumbra, Inc. (NYSE: PEN) today announced that Daniel Davis has been promoted and will add the title of Chief Commercial Officer to his existing title of President, North America. Mr. Davis joined Penumbra in 2007 as one of the first members of the Company’s sales team and has advanced […]
Recent
Boston Scientific announces agreement to acquire Penumbra, Inc.
Cardiac Biotech Solutions Activates China Production Pipeline for MyCardia AT and Moves into Final NMPA Submission Phase
Cereno Scientific Announces First Peer-Reviewed Publication on HDAC Inhibitor CS014: Antithrombotic Efficacy Without Bleeding Risk Supports Broad Potential in Cardiopulmonary Diseases
Popular
- No commented posts yet